🧠 AI clinical summary is being generated for this article and will appear shortly.
Source: MHRA  ·  Read original ↗

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk o…


This content is sourced from MHRA and reproduced for clinical reference. ClinicalIQ does not alter source content.

Share: 𝕏 Twitter/X 🔗 LinkedIn View on MHRA ↗

More in Diabetes / Metabolic